Skip to content

Nir Peled

Universidad de Las Palmas de Gran Canaria

2 papers in the Anchorcite directory, published between 2016 and 2018, cited 17,030 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Delvys Rodríguez‐Abreu · 2 papers
  • Rina Hui · 2 papers
  • Martin Reck · 1 paper
  • Andrew George Robinson · 1 paper
  • Tibor Csőszi · 1 paper
  • Andrea Fülöp · 1 paper
  • Maya Gottfried · 1 paper
  • Ali Tafreshi · 1 paper

Papers

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine · 2016 · 10,276 citations

    BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3…

  2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations

    BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…

Metadata from OpenAlex (CC0).